Roundtable Forum: Kevin DeGeeter, Oppenheimer & Co. Inc.; George Huang, Stansberry & Associates; Shivpreet Singh Kapoor, Ferris, Baker Watts Incorporated

Small & Mid-Cap Biotech Companies: Dr. Simos Simeonidis, Broadpoint Capital

Direct-Acting AntiVirals & Hepatitis C: Liisa Bayko, JMP Securities LLC

CEO Interviews (average 2,500 words): Top management from 13 sector firms examine the outlook for their firm and sector. Firms interviewed include: Amarillo Biosciences, Inc., Cleveland BioLabs, Inc., Encorium Group, Inc., Hemispherx Biopharma, Inc., Living Cell Technologies Limited, MannKind Corporation, Maxygen, Inc., Nabi Biopharmaceuticals, Opexa Therapeutics, Inc., Provectus Pharmaceuticals, Inc., SciClone Pharmaceuticals, Inc., Stellar Pharmaceuticals Inc., Vitro Diagnostics, Inc.

Topics covered: FDA approval process - Failures in oncology trials - Safety concerns - Public and private funding - PIPES and structured financing - Big Pharma partnerships - Development stage companies - Late-stage product companies - Technology platform companies - Outsourcing trends & CRO - Outlook for oncology companies - Urology companies and latest developments - Stock recommendations - Stocks to worry about

Companies covered: Genentech (DNA); ZymoGenetics ZGEN); AEterna Zentaris (AEZS); Sequenom (SQNM); ImmunoGen (IMGN); Genzyme (GENZ); Alnylam Pharmaceuticals (ALNY); Isis Pharmaceuticals (ISIS); Arena Pharmaceuticals (ARNA); Vertex Pharmaceuticals (VRTX); Progenics Pharmaceuticals (PGNX); Myriad Genetics (MYGN); Synta (SNTA).